MannKind Corporation (MNKD) Latest News: $40M Financing for Afrezza, Rating Reiterated by Zacks, Price Target & More

Editor’s Note: MannKind Corporation (NASDAQ:MNKD)

MannKind rewarded for positive Afrezza data with $40M financing (FierceBiotech)
MannKind’s positive take on interim Phase III data for its inhaled insulin Afrezza has a big sweetener tied to it. The Valencia, CA-based MannKind Corporation (NASDAQ:MNKD) has picked up a much-needed $40 million financing from Deerfield as a result of the data readout, the second of four tranches slated to provide MannKind with $160 million total. “The second tranche of convertible notes was subject to the achievement of Phase III data from studies 171 and 175 that met the primary efficacy endpoints of these studies and did not show any adverse safety issue that would reasonably be expected to prevent approval of Afrezza,” MannKind says in a release.

MannKind Corporation (NASDAQ:MNKD)MannKind Corp. Rating Reiterated by Zacks (MNKD) (The Utah People’s Post)
Zacks restated their neutral rating on shares of MannKind Corporation (NASDAQ:MNKD) in a report released on Wednesday, StockRatingsNetwork.com reports. Zacks currently has a $7.25 price objective on the stock. Zacks’ analyst wrote, “MannKind’s second quarter 2013 net loss of $0.16 per share was narrower than the year-ago loss of $0.23 but wider than the Zacks Consensus Estimate of a loss of $0.15. We expect investor focus to remain on Afrezza. MannKind completed both its late-stage studies (Affinity 1 and Affinity 2) on Afrezza and expects results from the studies soon. The company plans to resubmit the NDA for Afrezza later in the year. However, we remain concerned about the company’s over dependence on Afrezza.

MannKind Down 8 Percent on Analyst Downgrade But Traders Point Out a Flaw in the Logic (MNKD) (Breaking Finance News)
Shares of MannKind Corporation (NASDAQ:MNKD) are down more than 8 percent in afternoon trading Friday after an analyst downgrade. According to Seeking Alpha, Summer Street is suspicious of the results of its recently reported AFFINITY trial. Specifically, it said, that MannKind “released results on the injectable insulin and Dreamboat arms but withheld the results on the Medtone C-arm”

MLV Capital Increases MannKind Corp. Price Target to $11.00 (MNKD) (Zolmax)
Equities research analysts at MLV Capital raised their target price on shares of MannKind Corporation (NASDAQ:MNKD) from $8.00 to $11.00 in a research note issued to investors on Thursday, AnalystRatingsNetwork.com reports. The firm currently has a “buy” rating on the stock. MLV Capital’s price objective points to a potential upside of 65.66% from the company’s current price. A number of other firms have also recently commented on MNKD. Analysts at JMP Securities downgraded shares of MannKind Corp. from an “outperform” rating to a “market perform” rating in a research note to investors on Wednesday.

MannKind Corporation (NASDAQ:MNKD) Continues To Under pressure On High Volume (Market News Call)
Shares of MannKind Corporation (NASDAQ:MNKD) continues to be under pressure and slid another 9% in the opening session despite the company said that it satisfies conditions for second tranche of convertible note financing. Just after the news, the stock was up about 4% in pre-open session. The company announced that, pursuant to a Facility Agreement dated July 1, 2013 between Deerfield Private Design Fund II, L.P. and Deerfield Private Design International II, L.P. (collectively, “Deerfield”) and MannKind, the conditions that obligate Deerfield to purchase the second $40 million tranche of 9.75% senior secured convertible notes (the “Convertible Notes”) have now been satisfied.

Comments
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

The Highest Grossing Musicals on Broadway

The Most Successful Reality TV Stars

Cheapest Cities to Visit in the US

Most Expensive Summer Camps

Most Expensive Animals in the World

Most Expensive Specialty Crops in the World

Movies That Took Ages to Make

The Longest Hollywood Films Ever Made

Most Expensive Concert Stages

The Richest Bands of all Time

10 Most Corrupt Countries 2013 List

10 Countries with the Highest Quality of Life Index

Most Expensive Mattresses in the World

5 Smallest Countries by Land Area

The Ultimate Heartbreak Songs

Richest Teenagers in the World

10 Most Haunted Places in America

10 Best Places to Retire in Florida East Coast

Top 10 Places to See Before You Die

Top 8 Countries in the World Where Justice Prevails

10 Richest States in America

15 Wealthiest Countries in the World

Richest Singers in the World

Most Expensive Tasting Menu in New York City

Most Expensive Baby Items in the World

Most Expensive Hotel Suites in Vegas

Most Expensive Brunch in New York City

Most Expensive Beef Cuts in the World

25 Best Colleges to Get a Job

Top 10 US Supermarkets

The 25 Most Dangerous Cities in the World to Visit

Most Expensive Xbox Games

Top 11 Cities Where Billionaires Live

Top 10 Most Charitable Companies in America

Most Expensive Seafood in the World

The 10 Wildest Conspiracy Theories

The 10 Best Job Markets in the US

Top 10 Accounting Scandals of All Time

The 25 Biggest Cities in the World

Top 10 Best Paying Virtual Jobs

Most Expensive Leather Shoes in the World

Top 6 Things to Buy in March

The 10 Most Stressful Jobs in America – 2014 List

Top 10 Jobs for Introverted People

Top 10 Honeymoon Destinations in the World

Top 10 Highest Paying Jobs in the World

Most Expensive Day-Care in New York City

The 10 Cheapest Places to Retire Abroad

Top 10 Most Expensive Luxury Cars in the World – 2014

Killer Small Business Ideas

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!